Evolus, Inc.

EOLS

US30052C1071

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 18/07/2024 am IST			5-day change	1st Jan Change
11.95 ^USD	-0.58%		+9.13%	+13.49%

01/07	Evolus, Inc. Appoints Albert G. White III to its Board of Directors and Compensation Committee	CI
24/06	Evolus Completes FDA Premarket Approval Submission for Evolysse Dermal Fillers for 'Smile Lines'	MT

Evolus, Inc. has filed an IPO in the amount of $75 million.

January 09, 2018 at 10:30 am IST

Evolus, Inc. has filed an IPO in the amount of $75 million. Security Name: Common Stock Security Type: Common Stock

Latest news about Evolus, Inc.

Evolus, Inc. Appoints Albert G. White III to its Board of Directors and Compensation Committee	01/07	CI
Evolus Completes FDA Premarket Approval Submission for Evolysse Dermal Fillers for 'Smile Lines'	24/06	MT
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse? Dermal Filler Products	24/06	CI
Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain	12/06	CI
Evolus, Inc. Announces Positive Data from Pivotal Trial for First Two Evolysse? Dermal Filler Products at 2024 SCALE Meeting	20/05	CI
Certain Options of Evolus, Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2024.	11/05	CI
Certain Common Stock of Evolus, Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2024.	11/05	CI
Certain Restricted Stock Units of Evolus, Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2024.	11/05	CI
Evolus, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Transcript : Evolus, Inc., Q1 2024 Earnings Call, May 07, 2024	08/05
Earnings Flash (EOLS) EVOLUS Reports Q1 Revenue $59.3M, vs. Street Est of $57.3M	08/05	MT
Evolus, Inc. Reaffirms Financial Guidance for the Full Year 2024	08/05	CI
AbbVie raises annual profit forecast on strong Skyrizi sales	26/04	RE
Evolus, Inc. Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra- Strength" 40U Formulation of Jeuveau	18/04	CI
Evolus, Inc. Announces Board Changes	04/04	CI
Evolus Insider Sold Shares Worth $1,344,604, According to a Recent SEC Filing	22/03	MT
Transcript : Evolus, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 08:00 AM	13/03
Evolus Prices $50 Million Share Offering	11/03	MT
Sector Update: Health Care Stocks Steady Pre-Bell Friday	08/03	MT
Mizuho Securities Adjusts Evolus Price Target to $23 From $20, Maintains Buy Rating	08/03	MT
Evolus Q4 Net Loss Narrows, Revenue Increases; 2024 Revenue Guidance Affirmed; Shares Fall After Hours	08/03	MT
Evolus, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	08/03	CI
Transcript : Evolus, Inc., Q4 2023 Earnings Call, Mar 07, 2024	08/03
Earnings Flash (EOLS) EVOLUS Posts Q4 Revenue $61M, vs. Street Est of $61.1M	08/03	MT
Evolus, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	08/03	CI

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.

Sector

Pharmaceuticals

Calendar

31/07/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Evolus, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.95 USD

Average target price

22.29 USD

Spread / Average Target

+86.49%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
EVOLUS, INC.	+13.49%	75Cr
ELI LILLY AND COMPANY	+55.35%	82TCr
NOVO NORDISK A/S	+31.64%	60TCr
JOHNSON & JOHNSON	-0.10%	38TCr
MERCK & CO., INC.	+15.47%	32TCr
ABBVIE INC.	+13.10%	31TCr
ASTRAZENECA PLC	+15.51%	25TCr
NOVARTIS AG	+16.72%	23TCr
AMGEN INC.	+16.54%	18TCr
PFIZER, INC.	+4.31%	17TCr

Other Pharmaceuticals

Evolus, Inc.

Equities

EOLS

US30052C1071

Pharmaceuticals

Evolus, Inc. has filed an IPO in the amount of $75 million.

Latest news about Evolus, Inc.

Chart Evolus, Inc.

Company Profile

Income Statement Evolution

Ratings for Evolus, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals